KROS

Keros Therapeutics, Inc.

Keros Therapeutics, Inc. (KROS) has 2 SEC Form 4 filings (2 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 6, 2026.

  • Industry:Biotechnology
  • CEO:Jasbir S. Seehra
  • Employees:163
  • HQ:Lexington, MA, US
  • IPO:2020-04-08

Insider Buying

$10K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Unique Insiders

1

in the rolling window

Market Cap

$218.3M

latest known value

Source
Purchase$10KJun 17SEC ↗

Related companies

Keros Therapeutics, Inc. is in the Healthcare sector.